We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




D-Dimer Efficacy Evaluated for Disseminated Intravascular Coagulation Diagnosis

By LabMedica International staff writers
Posted on 17 Feb 2016
Print article
Image: Sysmex C-1500 automatic coagulation analyzer (Photo courtesy of Siemens Healthcare).
Image: Sysmex C-1500 automatic coagulation analyzer (Photo courtesy of Siemens Healthcare).
Image: The Innovance D-Dimer reagent set (Photo courtesy of Siemens Healthcare).
Image: The Innovance D-Dimer reagent set (Photo courtesy of Siemens Healthcare).
Disseminated intravascular coagulation refers to an acquired syndrome characterized by procoagulant substances entering the general circulation and leading to a systemic thrombotic process, which may be derived from or causing microvascular system damage.

D-dimer (D-D) was shown to be an important indicator for the diagnosis of overt disseminated intravascular coagulation (DIC) and non-overt DIC; however, its diagnostic cutoff value in the clinic is not clearly defined. The initiation of treatment in nonovert DIC leads to better outcome than in DIC and therefore, early diagnosis of non-overt DIC is pivotal for DIC prevention and treatment.

Clinical scientists at the Nanjing Medical University (Suzhou, China) enrolled 40 male and 80 female cases in each group (DIC, non-overt DIC, and non-DIC control group). All 360 cases were collected in Suzhou Municipal Hospital. The DIC group included patients clearly diagnosed with DIC who had been hospitalized in the intensive care unit (ICU); the non-overt DIC group comprised patients who were diagnosed later as DIC; and the non-DIC control group included patients who were convalescing after surgery, had normal liver and kidney function.

D-D, fibrinogen degradation products (FDP), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fg), thrombin time (TT), antithrombin (AT), and blood platelet count (PLT) of 360 cases were used to assess the diagnostic efficacy of Innovance D-Dimer reagent (Siemens Healthcare Diagnostics, Erlangen, Germany) for the diagnosis of DIC and non-overt DIC, compared to, or combined with, other DIC coagulation indicators. D-D was quantitatively analyzed using a Sysmex CA1500 automatic coagulation analyzer (Sysmex Corporation; Kobe, Japan) with an immunoturbidimetric method.

The investigators found that when D-D was greater than 3.0 μg/mL was used as the cutoff, the sum of diagnostic sensitivity and specificity reached maximum values for DIC and non-overt DIC, whereas the sum of misdiagnoses and missed diagnosis rate was minimal. Excluding D-D, AT, or Fg, but not TT, from the test combination reduced the diagnostic sensitivity of DIC or non-overt DIC by various degrees. Combining two factors, D-D of greater than 3.0 μg/mL and FDP of greater than 10 mg/L, increased the sensitivity and specificity for the diagnosis of DIC and non-overt DIC.

The authors concluded that monitoring D-D and FDP levels is useful for early intervention and improving microcirculation disturbance caused by disease. They propose that a cutoff value of D-D of greater than 3.0 μg/mL would be suitable for the InnovanceR D-D reagent in the laboratory; D-D in combination with FDP is meaningful for primary screening of non-overt DIC. The study was published on February 2, 2016, in the International Journal of Laboratory Hematology.

Related Links:

Nanjing Medical University 
Siemens Healthcare Diagnostics 
Sysmex Corporation 


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.